TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behavior and Exercise Versus Drug Treatment in Men With Nocturia
Brief Summary: Nocturia, waking at night from sleep to void, is a prevalent and troublesome symptom. Treatment with an alpha-adrenergic antagonist medication (α-blockers) is a standard therapy for LUTS in men, but α-blockers offer only limited reductions in nocturia. While combinations of multiple drugs could be used, many individuals wish to take fewer medications.

Participants in the BEDTiMe Nocturia Study will undergo a series of visits during which they will receive a combination of either standard drug therapy (or placebo) and a behavioral intervention tailored to help with nocturia or problems with nocturia. Participants will be evaluated for outcomes at 12 weeks and followed for six months.

This study will yield important information related to alternative treatments of nocturia in men, as well as novel information regarding the clinical importance of these nocturia reductions. This study has the potential to alter standards of care.


Options:
A: Arm Label: Dutasteride plus tamsulosin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dutasteride plus tamsulosin | Arm Label: Watchful waiting with escalation to tamsulosin; Type: EXPERIMENTAL; Interventions: Drug: tamsulosin | Intervention Type: DRUG; Name: Dutasteride plus tamsulosin; Assigned to Arm(s): Dutasteride plus tamsulosin | Intervention Type: DRUG; Name: tamsulosin; Assigned to Arm(s): Watchful waiting with escalation to tamsulosin
B: Arm Label: Behavioral and Exercise Therapy (M-BET); Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral, Drug: placebo | Arm Label: Drug Therapy w/ Behavioral Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: tamsulosin (alpha-adrenergic antagonist medication), Behavioral: placebo | Arm Label: Combination Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral, Drug: tamsulosin (alpha-adrenergic antagonist medication) | Intervention Type: BEHAVIORAL; Name: Behavioral; Assigned to Arm(s): Behavioral and Exercise Therapy (M-BET), Combination Therapy | Intervention Type: DRUG; Name: tamsulosin (alpha-adrenergic antagonist medication); Assigned to Arm(s): Combination Therapy, Drug Therapy w/ Behavioral Placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Behavioral and Exercise Therapy (M-BET) | Intervention Type: BEHAVIORAL; Name: placebo; Assigned to Arm(s): Drug Therapy w/ Behavioral Placebo
C: Intervention Type: BEHAVIORAL; Name: Self-management; Assigned to Arm(s): N/A
D: Arm Label: Behavioral Training; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral training | Arm Label: Drug Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin chloride, extended-release | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Behavioral Training | Intervention Type: DRUG; Name: Oxybutynin chloride, extended-release; Assigned to Arm(s): Drug Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial Comparing Intermittent Sedation and Daily Interruption of Sedation in Mechanically Ventilated Patients
Brief Summary: Sedation is very important in critical care. Critically ill patients are submitted to many stressor factors that have potential to affect longterm outcomes. However, oversedation is associated with increased morbidity, including increased time of mechanical ventilation and ICU stay and longterm psychological complications. Daily interruption of sedation is associated with less time under mechanical ventilation and less posttraumatic stress disorder. Intermittent sedation, when compared with continuous sedation, is also associated with decreased time of mechanical ventilation. The aim of this study is to compare intermittent sedation with daily interruption. Our primary endpoint is free-days of mechanical ventilation in 28 days.


Options:
A: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam
B: Arm Label: 1. Intermittent sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intermittent sedation | Arm Label: 2. Daily interruption of sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Daily interruption of sedation | Intervention Type: PROCEDURE; Name: Intermittent sedation; Assigned to Arm(s): 1. Intermittent sedation | Intervention Type: PROCEDURE; Name: Daily interruption of sedation; Assigned to Arm(s): 2. Daily interruption of sedation
C: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT
D: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial Comparing Intermittent Sedation and Daily Interruption of Sedation in Mechanically Ventilated Patients
Brief Summary: Sedation is very important in critical care. Critically ill patients are submitted to many stressor factors that have potential to affect longterm outcomes. However, oversedation is associated with increased morbidity, including increased time of mechanical ventilation and ICU stay and longterm psychological complications. Daily interruption of sedation is associated with less time under mechanical ventilation and less posttraumatic stress disorder. Intermittent sedation, when compared with continuous sedation, is also associated with decreased time of mechanical ventilation. The aim of this study is to compare intermittent sedation with daily interruption. Our primary endpoint is free-days of mechanical ventilation in 28 days.


Options:
A: Arm Label: 1. Intermittent sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intermittent sedation | Arm Label: 2. Daily interruption of sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Daily interruption of sedation | Intervention Type: PROCEDURE; Name: Intermittent sedation; Assigned to Arm(s): 1. Intermittent sedation | Intervention Type: PROCEDURE; Name: Daily interruption of sedation; Assigned to Arm(s): 2. Daily interruption of sedation
B: Intervention Type: PROCEDURE; Name: Daily interruption of sedation versus sedation algorithm; Assigned to Arm(s): N/A
C: Arm Label: No sedatation intervention; Type: OTHER; Interventions: Procedure: Sedation or no sedation during mechanical ventilation | Intervention Type: PROCEDURE; Name: Sedation or no sedation during mechanical ventilation; Assigned to Arm(s): No sedatation intervention
D: Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinare Sustained Release
Brief Summary: This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained release (DVS SR) or placebo for 12 weeks.


Options:
A: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
B: Intervention Type: BEHAVIORAL; Name: Care manager outreach and monitoring; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: desvenlafaxine succinate sustained release | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Genetic: Genotyping | Intervention Type: DRUG; Name: desvenlafaxine succinate sustained release; Assigned to Arm(s): 1 | Intervention Type: GENETIC; Name: Genotyping; Assigned to Arm(s): 2
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IBBIS MHC; Type: EXPERIMENTAL; Interventions: Behavioral: IBBIS mental health care and standard vocational rehabilitation | Arm Label: IBBIS integrated MCH and VR; Type: EXPERIMENTAL; Interventions: Other: Integrated mental health care and vocational rehabilitation | Intervention Type: BEHAVIORAL; Name: IBBIS mental health care and standard vocational rehabilitation; Assigned to Arm(s): IBBIS MHC | Intervention Type: OTHER; Name: Integrated mental health care and vocational rehabilitation; Assigned to Arm(s): IBBIS integrated MCH and VR

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-Term Effects of Iron and Zinc Supplementation During Infancy on Cognitive Performance and Growth 8 Years Later: A Follow-Up Study
Brief Summary: The hypotheses of this study are:

1. Compared to children who received a placebo, children who received iron or zinc or iron and zinc combined will perform better on cognitive tests and will have better growth status at ages 8 to 10 years.
2. Compared to children who received iron or zinc alone, children who received iron and zinc combined will perform differently on cognitive tests and will have different growth status at 8 ages 8 to 10 years
3. Compared to children who had poorer iron and zinc status or poorer growth status before and after supplementation during infancy, children who had better iron and zinc status or better growth status before and after supplementation during infancy will perform better on cognitive tests and will have better growth status at ages 8 to 10 years.
4. Compared to children who have lower iron and zinc status, poorer growth status, or low animal source intake at ages 8 to 10 years, children who have higher iron and zinc status, better growth status, or high animal source intake at ages 8 to 10 years will perform better on cognitive tests and will have better growth status.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: zinc sulphate dietary supplement; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iron sulphate-folic acid dietary supplement; Assigned to Arm(s): N/A
C: Arm Label: Fe, Zn, Fe+Zn, Placebo; Type: N/A; Interventions: N/A
D: Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Drug: Drug: Zinc (zinc sulphate) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Drug: Zinc (zinc sulphate); Assigned to Arm(s): Zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-Term Effects of Iron and Zinc Supplementation During Infancy on Cognitive Performance and Growth 8 Years Later: A Follow-Up Study
Brief Summary: The hypotheses of this study are:

1. Compared to children who received a placebo, children who received iron or zinc or iron and zinc combined will perform better on cognitive tests and will have better growth status at ages 8 to 10 years.
2. Compared to children who received iron or zinc alone, children who received iron and zinc combined will perform differently on cognitive tests and will have different growth status at 8 ages 8 to 10 years
3. Compared to children who had poorer iron and zinc status or poorer growth status before and after supplementation during infancy, children who had better iron and zinc status or better growth status before and after supplementation during infancy will perform better on cognitive tests and will have better growth status at ages 8 to 10 years.
4. Compared to children who have lower iron and zinc status, poorer growth status, or low animal source intake at ages 8 to 10 years, children who have higher iron and zinc status, better growth status, or high animal source intake at ages 8 to 10 years will perform better on cognitive tests and will have better growth status.


Options:
A: Arm Label: Fe, Zn, Fe+Zn, Placebo; Type: N/A; Interventions: N/A
B: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A
D: Arm Label: Multivitamins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins-vitamins B-complex, C, and E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins-vitamins B-complex, C, and E; Assigned to Arm(s): Multivitamins | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: REAL 3 : A Randomised Open-labelled Multicentre Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-gastric Cancer
Brief Summary: To determine whether adding panitumumab, an antibody against the epidermal growth factor receptor (EGFR), to standard chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX), improves the duration of survival of patients with advanced stomach and oesophageal cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: folinic acid; Assigned to Arm(s): 1, 2
B: Arm Label: CapeOx plus Lapatinib; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib, Drug: Capecitabine, Drug: Oxaliplatin | Arm Label: CapeOx plus Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Capecitabine, Drug: Oxaliplatin | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): CapeOx plus Lapatinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CapeOx plus Placebo | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): CapeOx plus Lapatinib, CapeOx plus Placebo | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): CapeOx plus Lapatinib, CapeOx plus Placebo
C: Arm Label: Arm A, - Modified DCF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin | Arm Label: ARM B - Parent DCF with G-CSF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen | Arm Label: Arm C - Modifid DCF + Trastuzumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab | Intervention Type: DRUG; Name: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Assigned to Arm(s): Arm A, - Modified DCF | Intervention Type: DRUG; Name: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen; Assigned to Arm(s): ARM B - Parent DCF with G-CSF | Intervention Type: DRUG; Name: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab; Assigned to Arm(s): Arm C - Modifid DCF + Trastuzumab
D: Arm Label: Arm A EOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: epirubicin, oxaliplatin, capecitabine (EOX) | Arm Label: Arm B EOX + panitumumab.; Type: ACTIVE_COMPARATOR; Interventions: Drug: EOX + panitumumab | Intervention Type: DRUG; Name: epirubicin, oxaliplatin, capecitabine (EOX); Assigned to Arm(s): Arm A EOX | Intervention Type: DRUG; Name: EOX + panitumumab; Assigned to Arm(s): Arm B EOX + panitumumab.

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Detection and Classification of Colon Polyps: A Comparison of High Definition White Light and Narrow Band Imaging (Endoscopic Trimodal Imaging; ETMI)
Brief Summary: Colon cancer is the third most common cancer in western society. To prevent colon cancer it is recommended for people to undergo a screening colonoscopy at the age of fifty. The purpose of the colonoscopy is to remove polyps, since some of these lesions are precancerous. Precancerous polyps are called adenomas. This method of prevention is effective, but the standard colonoscopy currently used does not detect all polyps. Studies have reported a polyp miss rate of about 24%. Furthermore, we are unable to distinguish precancerous polyps from benign polyps, also known as hyperplastic polyps, with standard colonoscopy. This results in all polyps being removed at time of colonoscopy, even the benign polyps.

To help improve the detection of colon polyps new endoscopic technologies have been developed. These technologies include high definition white light (HDWL)and high definition narrow band imaging (HDNBI). HDWL improves the overall resolution of the images seen during colonoscopy. HDNBI can help us better classify polyps by enhancing their tissue appearance as well as seeing small blood vessels and capillaries.

The goal of this study to determine if HDNBI imaging shows an increased polyp detection rate when compared to the current standard colonoscopy. In addition to develop a classification system to help better differentiate between precancerous polyps and their benign counterparts using HDWL and HDNBI.


Options:
A: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Polp removal and identification, Procedure: ETMI colonoscope (ETMI scope is a FDA approved device) | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: colon polyp removal, Procedure: ETMI colonoscope (ETMI scope is a FDA approved device) | Intervention Type: PROCEDURE; Name: Polp removal and identification; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: colon polyp removal; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: ETMI colonoscope (ETMI scope is a FDA approved device); Assigned to Arm(s): 1, 2
C: Arm Label: Group A - COLO, then TER; Type: EXPERIMENTAL; Interventions: Device: Third Eye Retroscope | Arm Label: Group B - TER, then COLO; Type: ACTIVE_COMPARATOR; Interventions: Device: Third Eye Retroscope | Intervention Type: DEVICE; Name: Third Eye Retroscope; Assigned to Arm(s): Group A - COLO, then TER, Group B - TER, then COLO
D: Intervention Type: PROCEDURE; Name: Colonoscopy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HARMONY Study (Hypertension Analysis of Stress Reduction Using Mindfulness Meditation and Yoga)
Brief Summary: The purpose of this study is to determine if Mindfulness Based Stress Reduction (MBSR) is an effective intervention for lowering blood pressure in early unmedicated hypertensives.


Options:
A: Arm Label: Enhanced Usual Care (EUC); Type: OTHER; Interventions: Behavioral: Enhanced Usual Care, Diagnostic Test: Actigraph | Arm Label: Stress Management; Type: OTHER; Interventions: Behavioral: Stress Management, Diagnostic Test: Actigraph | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care (EUC) | Intervention Type: BEHAVIORAL; Name: Stress Management; Assigned to Arm(s): Stress Management | Intervention Type: DIAGNOSTIC_TEST; Name: Actigraph; Assigned to Arm(s): Enhanced Usual Care (EUC), Stress Management
B: Arm Label: Distress management; Type: EXPERIMENTAL; Interventions: Behavioral: A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives; Assigned to Arm(s): Distress management
C: Arm Label: Early Intervention, MBSR therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Stress Reduction (MBSR) Therapy | Arm Label: Delayed Treatment Arm, MBSR Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness Based Stress Reduction (MBSR) Therapy | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Stress Reduction (MBSR) Therapy; Assigned to Arm(s): Delayed Treatment Arm, MBSR Therapy, Early Intervention, MBSR therapy
D: Arm Label: Standard lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard lifestyle intervention | Arm Label: Mind-body lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mind-body lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Mind-body lifestyle intervention; Assigned to Arm(s): Mind-body lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Standard lifestyle intervention; Assigned to Arm(s): Standard lifestyle intervention

Answer: C